Latest news with #Balstilimab
Mint
a day ago
- Business
- Mint
Zydus to Enter Global Biologics CDMO Business Plans
New Jersey, United States & Ahmedabad, Gujarat, India – Business Wire India Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus) today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (Nasdaq: AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufacturing for biologics thereby adding a sustainable growth driver for the group. Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Under the terms of the agreement, Zydus will acquire two state-of-the-art biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California (US) for an upfront consideration of US$75 million and contingent payment of US$50 million to be paid over three years subject to achievement of certain revenue milestone. This acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and establishes a key presence in California, a leading global biotechnology hub. This strategic move enables Zydus to leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally. With this acquisition Zydus will now become a one stop solution provider across the entire development spectrum of biologics, right from pre-clinical to toxicology studies, clinical development and now CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. The facilities come with an experienced professional team with strong capabilities and requisite industry expertise to deliver high-quality biologics development and manufacturing services to global biotech and pharmaceutical companies. As a part of transaction Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry." The global biologics CDMO market is experiencing significant growth, driven by the increasing complexity of therapies, the rise of biologics in clinical pipelines, and a growing number of emerging biotech companies lacking internal manufacturing capabilities. According to the Global Biologics CDMO Market Size is expected to be worth around US$ 84.9 Billion by 2034, growing at a CAGR of 15.7% between 2025 to 2034. As demand surges for reliable, agile, and scalable partners, Zydus' entry into this space positions it to tap into significant long-term growth opportunities and support innovation across the global biopharmaceutical landscape. About Zydus Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: About Agenus Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients. For more details visit: Forward-Looking Statements: This press release contains forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the successful integration of the acquired business, market conditions, and other factors. Sujatha Rajesh (Media Relations), Zydus Lifesciences Limited, +91-9974051180 Arvind Bothra (Investor Relations), Zydus Lifesciences Limited, +91-7045656895
Indian Express
2 days ago
- Business
- Indian Express
Zydus announces plan to acquire US manufacturing units of Agenus Inc
Zydus Lifesciences on Tuesday announced its plan to acquire Agenus Inc's US-based biologics CMC (Chemistry, Manufacturing, and Control) facilities, marking the Gujarat-based firm's entry into the global biologics contract development and manufacturing organisation (CDMO) business. Agenus Inc. is a clinical-stage immuno-oncology company developing immune therapies, which effectively combat cancer. Zydus, in a statement, said it is set to acquire two biologics manufacturing facilities, located in Emeryville and Berkeley, California, for an upfront consideration of USD 75 million and contingent payment of USD 50 million to be paid over three years, 'subject to achievement of certain revenue milestones'. With this acquisition, Zydus claims it will become a one-stop solution provider across the entire development spectrum of biologics, right from preclinical to toxicology studies, clinical development and now manufacturing. Zydus's CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities, according to the statement. Further, Zydus will also become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). In addition, Zydus will have the first right of negotiation to manufacture any of the future pipeline products developed by Agenus, the statement further read. Dr Sharvil Patel, Managing Director (MD) of Zydus Lifesciences, said, 'The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritising patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry.'
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Zydus enters biologics CDMO market with $125 million acquisitions
Zydus Lifesciences has announced its entry into the global biologics contract development and manufacturing organisation (CDMO) market with a planned acquisition of two manufacturing facilities from US-based Agenus for up to $125 million (around ₹1,070 crore). Under the agreement, Zydus will acquire Agenus' biologics facilities in Emeryville and Berkeley, California, for an upfront payment of $75 million (₹642 crore). It will come with an additional $50 million (₹428 crore) payable over three years, contingent upon achieving certain revenue milestones. The acquisition gives Zydus immediate biologics manufacturing capabilities and a base in California, considered a major hub for biotechnology in the US. The company said the acquired facilities would allow it to offer end-to-end services from pre-clinical development through largescale commercial manufacturing. The CDMO business will be housed under a new independent entity. As part of the transaction, Zydus will also become the exclusive contract manufacturer for two of Agenus' late-stage immuno-oncology candidates, Botensilimab and Balstilimab. It will hold the first right of negotiation for future pipeline products. The acquired facilities include an experienced professional team, which Zydus plans to expand. The company said it expects to create additional jobs and contribute to the local economy of California. Sharvil Patel, managing director, Zydus Lifesciences, said, 'The acquisition will give Zydus a strategic foothold in the US and enhance our ability to partner with innovation-centric entities, advancing new products and prioritising patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the needs of the global biopharmaceutical industry.' According to estimates cited by Zydus, the global biologics CDMO market is projected to grow at a compound annual growth rate (CAGR) of 15.7 per cent between 2025 and 2034, reaching around $84.9 billion by 2034. The market's growth is being driven by increasing complexity of therapies, a shift towards biologics, and limited manufacturing infrastructure among small biotech companies.
The Hindu
2 days ago
- Business
- The Hindu
Zydus to acquire 2 biologics manufacturing units in U.S. from Agenus for $125 million
Zydus Lifesciences plans to acquire Nasdaq-listed clinical-stage immuno-oncology firm Agenus's two biologics manufacturing facilities in California, U.S. for $125 million to enter the global biologics contract development and manufacturing organization (CDMO) business. The move enables it to leverage supply chain dynamics and a favourable geopolitical environment to expand reach in the U.S. and globally. The facilities in Emeryville and Berkeley will be acquired for an upfront consideration of $75 million and contingent payment of $50 million, to be paid over three years subject to achievement of certain revenue milestone. Zydus said the acquisition, through a subsidiary, will provide access to advanced biologics manufacturing capabilities and establish a key presence in the leading global biotechnology hub of California. Also as a part of the transaction Zydus will become an exclusive contract manufacturer for Agenus and provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Create jobs, spur local economy With the acquisition Zydus will become a one stop solution provider across the entire development spectrum of biologics, from pre-clinical to toxicology studies, clinical development to manufacturing. Zydus said it intends to further expand the team and help create new jobs in the region and contribute to the local economy. Zydus' CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. 'The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions,' MD Sharvil Patel said. In a parallel development, Zydus Lifesciences has entered into a definitive agreement with Agenus Inc. to secure exclusive commercial rights for India and Sri Lanka for BOT and BAL.
Mint
2 days ago
- Business
- Mint
Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy
Zydus Lifesciences announced on Tuesday it is acquiring two biologics contract manufacturing facilities in California from US-based Agenus Inc for a total consideration of up to $125 million. The deal includes an upfront payment of $75 million, with the remaining $50 million to be paid over the following three years. The Ahmedabad-based pharmaceutical firm said the acquisition will establish its presence in the rapidly-expanding global biologics contract development and manufacturing organization (CDMO) sector. Zydus is also acquiring a 5.9% stake in Agenus for $16 million, through its wholly-owned subsidiary Zynext Ventures USA LLC, it said in an exchange filing on Tuesday. The drugmaker has also entered into a licensing agreement with Agenus to commercialise its investigational Botensilimab (BOT) and Balstilimab (BAL) combination therapy in India and Sri Lanka. Agenus is a clinical-stage immuno-oncology company committed to developing immune therapies against cancer. The move to acquire biologics manufacturing facilities in the US aligns with Zydus' strategic focus on biologics as a key growth driver this year. Also Read: Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial "The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California," managing director Sharvil Patel said in a statement. 'This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry," he added. Additionally, the acquisition gives the company a stronger manufacturing presence in the US, amid ongoing uncertainties over potential American tariffs on pharmaceutical imports. In the company's earnings call last month, Patel had said the company is evaluating opportunities for local manufacturing in the US. 'We have committed to making a good amount of investments in the US with our foray into specialty and other areas," he told investors. Exclusive manufacturer to Agenus Under the terms of the agreement, Zydus will acquire two modern biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California, for an upfront consideration of $75 million and contingent payment of $50 million to be paid over three years subject to achievement of certain revenue milestone. The acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and a foothold in California, a leading global biotech hub. The move also enables Zydus to 'leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally," it said in the release. Also Read: KKR provides $600 mn financing to Manipal Group to fuel its corporate expansion The CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. As part of the transaction, Zydus will become the exclusive contract manufacturer for Agenus, and provide manufacturing services for the clinical and commercial supply of two identified Phase-3 ready immuno-oncology products - Botensilimab and Balstilimab. Zydus will also have the first right of negotiation to manufacture any of the future pipeline products by Agenus. Agenus reported a turnover of $103.46 million in 2024, according to the exchange filing. Agenus' lead programme comprising Botensilimab and Balstilimab is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. The platform, which is currently in advanced clinical trials, has demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and patients who have undergone neoadjuvant, or primary, therapy. As part of the licensing agreement inked with Agenus, Zydus will be responsible for clinical development and regulatory approvals of the licensed products in India and Sri Lanka and will pay 5% royalty on net sales upon successful approval and commercialization. Also Read: Young heirs take charge as Indian pharma firms plan succession Zydus will expand the reach of the therapy within its initial indications, as well as drive its expansion into other high unmet need indications and earlier lines of treatment, including primary treatments, the company said.
